Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Progressive Medical Concepts LLC

Neither a doctor nor a teaching hospital

Research payments

$36,562,965

425 payments

Through program year 2025, Progressive Medical Concepts LLC is reported as receiving $36,562,965 in research payments, across 425 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $9,065,187 41
2024 Research $5,241,007 29
2023 Research $11,369,700 82
2022 Research $4,326,703 59
2021 Research $3,834,958 77
2020 Research $1,218,330 52
2019 Research $1,507,081 85

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $33,535,404 114 payments
  2. Avid Radiopharmaceuticals, Inc. $987,009 3 payments
  3. Regeneron Pharmaceuticals, Inc. $599,579 62 payments
  4. Amgen Inc. $457,152 2 payments
  5. Pfizer Inc. $231,605 72 payments
  6. GRT US Holding, Inc. $205,846 49 payments
  7. Ucb SA $169,039 7 payments
  8. Corcept Therapeutics $101,458 30 payments
  9. Ionis Pharmaceuticals, Inc. $77,343 13 payments
  10. GlaxoSmithKline, LLC. $70,743 28 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $4,995,740 2 payments
  2. A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3372993 in Participants With Alzheimer's Disease $4,208,940 9 payments
  3. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $4,021,275 2 payments
  4. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $3,177,905 10 payments
  5. A Multiple-Dose Dose-Escalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Ly3372993 in Participants With Alzheimer's Disease $2,107,686 2 payments
  6. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $2,067,228 6 payments
  7. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $1,935,893 5 payments
  8. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,738,878 3 payments
  9. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,593,732 2 payments
  10. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $1,575,233 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record